FOLFIRI方案二线治疗复发转移性结肠直肠癌疗效观察

FOLFIRI as a second-line chemotherapy in the treatment ofrefractory or metastatic colorectal cancer

目的评价FOLFIRI方案(伊立替康+亚叶酸钙+5-氟尿嘧啶)用于奥沙利铂治疗失败的复发转移性结肠直肠癌治疗的临床疗效和安全性。方法接受奥沙利铂化疗失败的结肠直肠癌患者30例,给予FOLFIRI方案(伊立替康180 mg/m2静脉滴注,第一天;亚叶酸钙200 mg/m2静脉滴注2 h,第一天;5-氟尿嘧啶400 mg/m2静脉推注后,2.4～3.6 g/m2持续静脉滴注46 h)治疗,14 d为一疗程。治疗4疗程后评价疗效,并观察不良反应。结果患者有效率为30%,中位肿瘤进展时间为3.2月,中位总生存期为12.3月。不良反应主要有中性粒细胞减少、迟发性腹泻及乙酰胆碱综合征。结论 FOLFIRI方案用于奥沙利铂治疗失败的复发转移性结肠直肠癌二线治疗疗效肯定,耐受性好。

Objective To evaluate the efficacy and safety of FOLFIRI as a second-line chemotherapy in the treatment of refractory or metastatic colorectal cancer.Methods Thirty patients with refractory or metastatic colorectal cancer failed to oxaliplatin-based chemotherapy were treated with FOLFIRI（irinotecan 180 mg/m^2 ＋ leucovorin 200 mg/m^2 on the first day＋ 5-FU 400 mg/m^2 bolus followed with 5-FU 2.4~3.6 g/m^2 in 46 hours）.Results The effective rate of treatment was 30%,the median time to progression was 3.2 months,and the median survival time was 12.3 months.The major adverse reactions were neutropenia,delayed diarrhea and acetylcholine syndrome.Conclusion FOLFIRI as a second-line chemotherapy in the treatment of refractory or metastatic colorectal cancer is effective and well tolerated.